OncLive TV

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Kaushal Parikh, MD, MBBS, discusses the KRAS inhibitors AMG 510 and MRTX849 in lung cancer.

I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Ulka Vaishampayan, MD, discusses the utility of immunotherapy in metastatic renal cell carcinoma.

Nabil P. Rizk, MD, MS, MPH, discusses criteria for surgical resection in lung cancer.

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

Sham Mailankody, MBBS, discusses research regarding the BCMA CAR T-cell therapy bb2121 in patients with relapsed/refractory multiple myeloma.

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Andre Goy, MD, MS, discusses treatment approaches for older patients with mantle cell lymphoma.